Michael White

Michael White

Company: Biosplice Therapeutics

Job title: Chief Scientific Officer

Seminars:

Live Q&A & Panel Discussion: The Value of Splicing Modulators for Therapeutics & Future Applications 4:45 pm

Targeting RNA splicing for disease application intervention has proven a valuable therapeutic intervention. It is now essential to review the clinical landscape of successes which exists with targeting the RNA spliceosome, consider various approaches and motifs being harnessed to target diseases beyond SMA and review future applicability of this modality.Read more

day: Day One

Drugging Alternative Splicing in Degenerative Disease & Cancer 4:15 pm

Alternative pre-mRNA splicing is commonly associated with human disease CLK/DYRK family kinases selectively modulate pre-mRNA splice junction selection by the spliceosome in both normal and diseased tissue contexts Emerging highly specific small molecule CLK/DYRK inhibitors indicate these kinases are a druggable intervention point for alternative splicing associated diseasesRead more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.